Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies
Bright Minds to Announce Topline Results for BMB-101 Phase 2 Trial in Absence Seizures and Developmental and Epileptic Encephalopathies on Tuesday, January 6, 2026
Bright Minds Biosciences Announces BMB?201 Outperforms Sumatriptan in Validated Preclinical Vascular Headache Model
Brixton Metals Enters into Option Agreement to Acquire a 100% Interest in the Silver Focused Silvergruvan Project in Sweden
Nevada Sunrise Announces Results of Soil Sampling Program at the Fivemile Gold Project, Cortez Mining District, Nevada
